- Home
- AHCO vs DNTH Comparison
AHCO vs DNTH Comparison
Compare AHCO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHCO
- DNTH
- Stock Information
- Founded
- AHCO 2012
- DNTH 2015
- Country
- AHCO United States
- DNTH United States
- Employees
- AHCO N/A
- DNTH N/A
- Industry
- AHCO Medical/Nursing Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- AHCO Health Care
- DNTH Health Care
- Exchange
- AHCO Nasdaq
- DNTH Nasdaq
- Market Cap
- AHCO 1.2B
- DNTH 1.0B
- IPO Year
- AHCO N/A
- DNTH N/A
- Fundamental
- Price
- AHCO $9.29
- DNTH $37.16
- Analyst Decision
- AHCO Strong Buy
- DNTH Strong Buy
- Analyst Count
- AHCO 5
- DNTH 9
- Target Price
- AHCO $13.40
- DNTH $61.57
- AVG Volume (30 Days)
- AHCO 864.3K
- DNTH 945.4K
- Earning Date
- AHCO 11-04-2025
- DNTH 11-06-2025
- Dividend Yield
- AHCO N/A
- DNTH N/A
- EPS Growth
- AHCO N/A
- DNTH N/A
- EPS
- AHCO 0.54
- DNTH N/A
- Revenue
- AHCO $3,240,757,000.00
- DNTH $4,854,000.00
- Revenue This Year
- AHCO $0.98
- DNTH N/A
- Revenue Next Year
- AHCO $6.53
- DNTH N/A
- P/E Ratio
- AHCO $17.32
- DNTH N/A
- Revenue Growth
- AHCO N/A
- DNTH 17.87
- 52 Week Low
- AHCO $7.11
- DNTH $13.37
- 52 Week High
- AHCO $11.70
- DNTH $38.59
- Technical
- Relative Strength Index (RSI)
- AHCO 49.33
- DNTH 83.51
- Support Level
- AHCO $9.08
- DNTH $22.81
- Resistance Level
- AHCO $9.59
- DNTH $24.81
- Average True Range (ATR)
- AHCO 0.31
- DNTH 2.67
- MACD
- AHCO 0.00
- DNTH 1.45
- Stochastic Oscillator
- AHCO 49.28
- DNTH 90.94
About AHCO AdaptHealth Corp.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.